MOTS-C

MOTS-c

MOTS-c is a mitochondrial-encoded peptide derived from the 12S rRNA region of mitochondrial DNA, recognized for its dual identity as a longevity peptide and exercise mimetic that influences cellular energy regulation and metabolic signaling [2], [5]. Licensed practitioners who want to buy MOTS-c can contact Medical Spa Rx’s professional support team for guidance on sourcing from qualified suppliers and for access to supporting documentation, including purity information. Browse this page to learn more about MOTS-c and its research applications through the overview and FAQ sections below.

What Is MOTS-C? Mitochondrial-Derived Peptide for Longevity & Performance

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid mitochondrial-derived peptide encoded by the MT-RNR1 gene of the mitochondrial 12S rRNA, distinct from nuclear DNA [5]. It functions as an exercise-mimetic and metabolic signaling peptide, studied for its effects on longevity, insulin resistance, mitochondrial health, and physical performance. Endogenous MOTS-c levels increase in skeletal muscle and circulation during physical exercise and decline with age, establishing a physiological rationale for supplementation research in longevity and metabolic medicine contexts [2].

The discovery of MOTS-c contributed to a paradigm shift in understanding mitochondria as endocrine-like signaling organelles rather than solely energy producers. MOTS-c is a notable example of a mitochondrial-derived peptide for therapeutic exploitation, demonstrating that mitochondrial DNA encodes bioactive peptides that influence systemic metabolism [5].

What is MOTS-c Used For?

Primary research applications include:

• Longevity and anti-aging protocols (Animal model / observational human data): Studied for its role in addressing age-related metabolic decline associated with falling endogenous MOTS-c levels [2]; as of June 2026, no published peer-reviewed results from completed human interventional RCTs are available — the primary human data remains observational, and a Phase 2a trial (NCT07505745, EX-MOTS-2A-001) evaluating MOTS-c for insulin sensitivity in prediabetes with overweight/obesity is currently recruiting, with primary completion expected February 2027 [6]
• Insulin resistance (Animal model / preclinical): AMPK-mediated improvements in glucose uptake and insulin sensitivity in obesity and insulin resistance models [1]
• Physical performance (Animal model / observational human data): Reynolds et al. at the USC Leonard Davis School of Gerontology (Nat Commun, 2021) reported that MOTS-c treatment improved exercise capacity in mice across all age groups and that exercise induces endogenous MOTS-c expression in humans; no interventional human performance trial has been completed [2]
• Mitochondrial health (Preclinical): Studied for its role in metabolic flexibility and mitochondrial efficiency in skeletal muscle [1], [2]

MOTS-c remains a research compound. It is not FDA-approved for any therapeutic indication, and compounding pharmacies are restricted from preparing it for human use [4]. Current evidence consists of preclinical studies and observational human data, with Phase II interventional trials ongoing but not yet published.

What Does MOTS-C Peptide Do? Mechanism of Action & Metabolic Benefits

The primary mechanism involves the activation of AMPK (AMP-activated protein kinase) through inhibition of the folate cycle, leading to purine depletion and altered ATP/AMP ratios — thereby triggering a cascade of downstream metabolic effects [1], [5].

Key mechanistic effects by evidence tier:

• AMPK activation → improved insulin sensitivity (Animal model / preclinical): Enhanced glucose uptake in skeletal muscle via GLUT4 and increased fatty acid utilization; proposed to address metabolic root causes of insulin resistance [1]
• Mitochondria-to-nucleus retrograde signaling (Preclinical/observational): Under conditions of metabolic stress, MOTS-c translocates to the nucleus where it activates gene expression programs governing energy homeostasis and cellular adaptation [5]; Reynolds et al. confirmed MOTS-c regulates nuclear genes related to metabolism and proteostasis in skeletal muscle [2]
• Muscle metabolism support (Animal model / observational human): Studies suggest MOTS-c supports metabolic flexibility and mitochondrial efficiency in skeletal muscle; exercise induces MOTS-c expression in both skeletal muscle and circulation in humans [2]
• Exercise-mimetic activity (Animal model): Reynolds JC et al. at the USC Leonard Davis School of Gerontology (Nat Commun. 2021;12(1):470) demonstrated that MOTS-c treatment improved exercise capacity in mice across young, middle-aged, and old age groups; in humans, exercise induces endogenous MOTS-c expression approximately 12-fold in skeletal muscle and significantly increases circulating levels [2]

As of mid 2026, no completed human interventional efficacy trials (RCTs) have been published for MOTS-c. All proposed human benefits should be treated as investigational and extrapolated from animal models and observational human data rather than established therapeutic outcomes.

MOTS-C Dosage, When to Take & Safety Overview

MOTS-c is a research compound. No FDA-approved prescribing protocol exists, and compounding pharmacies are restricted from preparing it for human therapeutic use [4]. All dosing information below is practitioner-reported and research-extrapolated; individualized clinical assessment is required.

MOTS-c Dosage (practitioner-reported; not clinically validated)

• Common ranges cited: 5–10 mg subcutaneously, 2–3 times weekly, or 5 mg every 5 days
• No standardized dose or frequency has been validated in controlled human trials

When to Take MOTS-c Peptide

• Morning dosing is frequently discussed for alignment with circadian metabolic activity
• Pre-exercise timing has been explored in performance-oriented research contexts, given the peptide’s exercise-mimetic characterization
• No validated human protocol currently establishes an optimal administration schedule

Reconstitution and Storage

• Reconstitute with bacteriostatic water under sterile conditions
• Store at 2–8°C post-reconstitution; protect from light
• Practitioner-reported protocols range from continuous weekly administration to cycling approaches with scheduled breaks

MOTS-c Side Effects

• Generally well tolerated in animal research; no completed human safety trials exist
• Injection site reactions consistent with subcutaneous peptide administration: mild redness, temporary swelling, localized tenderness
• Among individuals who report purchasing MOTS-c online, reported side effects include increased heart rate, heart palpitations, insomnia, and fever [3]
• No long-term human safety data exist; this limitation must be communicated clearly in any research protocol discussion

WADA status (as of June 2026)

MOTS-c is strictly prohibited at all times — both in-competition and out-of-competition — under Section 4.4 Metabolic Modulators, 4.4.1 (Activators of AMPK), on the WADA Prohibited List, in the same prohibited class as AICAR [3]. Athletes cannot receive a Therapeutic Use Exemption (TUE) because MOTS-c has no approved medical indications. Tested athletes using MOTS-c will incur an anti-doping rule violation [3].

Legal Status of MOTS-C Peptide

Regulatory status as of June 2026:

• United States: Not FDA-approved for any therapeutic indication; classified as Category 2 (significant safety concerns) on the FDA’s bulk drug substances list, meaning compounding pharmacies are restricted from preparing MOTS-c for human use [4]
• Australia: Not TGA-approved for therapeutic use; practitioners should verify current compounding guidance as regulatory frameworks may evolve
• WADA: Strictly prohibited at all times under Section 4.4.1 (AMPK activators); no TUE available; anti-doping rule violation for all tested athletes [3]

Practitioners should routinely confirm current legal classifications before incorporating MOTS-c into any research or clinical protocol discussion.

Important for competitive athletes: If you are subject to WADA-governed anti-doping testing, do not use MOTS-c. Use will result in an anti-doping rule violation regardless of therapeutic intent. No TUE is available, and the prohibition applies both in- and out-of-competition [3].

MOTS-C vs. SS-31 and MOTS-C vs. NAD

Several mitochondrial-focused compounds are used in longevity and metabolic research. Comparing MOTS-C with SS-31 and NAD helps clarify their distinct mechanisms, potential applications, and protocol considerations.

MOTS-C vs. SS-31

MOTS-c and SS-31 both belong to the broader category of mitochondrial longevity peptides, but they operate through fundamentally different mechanisms. MOTS-c primarily influences AMPK activation and mitochondria-to-nucleus metabolic signaling, addressing the metabolic signaling and insulin sensitivity layer of mitochondrial function [1], [5]. SS-31, by contrast, binds cardiolipin within the inner mitochondrial membrane to stabilize electron transport chain function and reduce oxidative stress — a structural membrane-level intervention rather than a signaling one.

Practitioners focused on metabolic aging, insulin resistance, or exercise adaptation may favor MOTS-c; those addressing mitochondrial structural decline, oxidative injury, or electron transport chain dysfunction may prioritize SS-31. In comprehensive mitochondrial health protocols, the two are often viewed as complementary because they target distinct biological layers.

MOTS-C vs. NAD

MOTS-c and NAD approach longevity through different entry points into mitochondrial biology. MOTS-c functions through peptide-mediated AMPK signaling and metabolic adaptation, influencing the signaling layer of energy regulation [1]. NAD+, by contrast, serves as a critical cellular cofactor involved in sirtuin activation, PARP-mediated DNA repair, and mitochondrial biogenesis — replenishing a substrate whose depletion is a central driver of age-related mitochondrial decline.

Research subjects focused on metabolic resilience, exercise adaptation, and insulin sensitivity may align more closely with MOTS-c-centered strategies; those emphasizing cellular repair, mitochondrial biogenesis, and restoration of age-related NAD+ depletion may prioritize NAD-based approaches. In longevity medicine, combined protocols are sometimes explored because the two compounds act on complementary layers.

Where Can Practitioners Buy MOTS-c Online?

MOTS-c is a research-grade compound available for purchase by qualified professionals only and is not intended for personal, therapeutic, or clinical use. Practitioners looking to order MOTS-c from a verified research-grade supplier should source only from vendors who can provide verifiable purity documentation, LOT number traceability, and a certificate of analysis for each batch. These standards are especially important when buying online, where supplier transparency and manufacturing quality vary widely.

Medical Spa Rx’s professional support team offers sourcing guidance and documentation support to help licensed professionals identify qualified suppliers and evaluate wholesale buying options. Practitioners are encouraged to contact Medical Spa Rx’s professional support team directly for guidance on supplier standards, documentation requirements, and research-grade sourcing considerations when looking to buy MOTS-c wholesale.

FAQs

1. What is MOTS-c?

MOTS-c is a 16-amino-acid mitochondrial-encoded peptide produced from the MT-RNR1 gene of the mitochondrial 12S rRNA, distinct from nuclear DNA [5]. Endogenous levels increase during physical exercise and decline with age [2]. It is studied for effects on longevity, metabolic health, insulin sensitivity, and exercise-mimetic applications in preclinical and observational research. MOTS-c is not FDA-approved, is restricted from compounding for human use, and is prohibited at all times by WADA under Section 4.4.1 [3], [4].

2. What does the MOTS-c peptide do?

MOTS-c primarily activates AMPK via inhibition of the folate cycle, thereby driving downstream improvements in insulin sensitivity, glucose uptake, and fat oxidation in animal models [1], [5]. Reynolds et al. (Nat Commun, 2021) reported that MOTS-c treatment improved physical performance in mice across all age groups, and that exercise induces endogenous MOTS-c expression in humans [2]. No completed human interventional trials have been published as of June 2026.

3. What is the MOTS-c peptide used for?

Researchers investigate MOTS-c for longevity protocols, metabolic health, insulin resistance, physical performance, and healthy aging in preclinical and observational settings. As of June 2026, no published peer-reviewed results from completed human interventional RCTs are available; the primary human data remain observational. An active Phase 2a trial (NCT07505745, EX-MOTS-2A-001) evaluating MOTS-c for insulin sensitivity in prediabetes with overweight/obesity is currently recruiting, with primary completion expected in February 2027. Practitioner-reported applications exist within broader mitochondrial health protocols, though controlled human evidence remains absent.

4. What is the MOTS-c dosage?

Practitioner-reported protocols cite subcutaneous doses of approximately 5–10 mg, 2–3 times weekly or 5 mg every 5 days. These dosing approaches are research-extrapolated, not supported by FDA-approved prescribing information, and MOTS-c is restricted from compounding for human therapeutic use [4]. Individualized clinical assessment is essential.

5. When to take MOTS-c peptide?

Morning administration is frequently discussed for alignment with natural metabolic activity and circadian rhythms. Some performance-focused protocols explore pre-exercise timing given the peptide’s exercise-mimetic characterization in animal research [2]. No validated human protocol establishes an optimal administration schedule.

6. How does MOTS-c compare to SS-31?

MOTS-c addresses metabolic signaling through AMPK activation and mitochondria-to-nucleus retrograde signaling, with proposed applications in insulin resistance and exercise adaptation [1], [5]. SS-31 targets mitochondrial membrane integrity by binding cardiolipin and stabilizing the electron transport chain. Both support mitochondrial health through complementary mechanisms and may be considered together in comprehensive longevity protocols.

7. How does MOTS-c compare to NAD?

MOTS-c influences metabolic adaptation through AMPK-mediated signaling [1]; NAD functions as a cofactor supporting sirtuin activation, DNA repair, and mitochondrial biogenesis. These compounds address different entry points into mitochondrial longevity pathways. Many clinicians consider them complementary components of comprehensive mitochondrial health strategies.

Sources

1. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443–454. doi:10.1016/j.cmet.2015.02.009
2. Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470. Published 2021 Jan 20. doi:10.1038/s41467-020-20790-0
3. US Anti-Doping Agency. What is the MOTS-c peptide? Published January 15, 2024. https://www.usada.org/spirit-of-sport/what-is-mots-c-peptide/
4. US Food and Drug Administration. Safety Risks Associated with Certain Bulk Drug Substances Nominated for Use in Compounding. https://www.fda.gov/drugs/human-drug-compounding/safety-risks-associated-certain-bulk-drug-substances-nominated-use-compounding
5. Mohtashami Z, Singh MK, Salimiaghdam N, Ozgul M, Kenney MC. MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases. Int J Mol Sci. 2022;23(19):11991. Published 2022 Oct 9. doi:10.3390/ijms231911991
6. National Institutes of Health. NCT07505745: MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity. ClinicalTrials.gov. Published March 31, 2026. https://clinicaltrials.gov/study/NCT07505745

The page and all of its displayed contents are for medical professionals, designed to inform only, and not as a replacement for medical advice.